Henlius | 复宏汉霖 is a leading Chinese biopharmaceutical company focused on providing high-quality and innovative biologics to global patients. With a product range covering oncology and autoimmune diseases, Henlius has made significant contributions to the rapid development of the Chinese biopharmaceutical industry. Henlius has successfully launched four domestically developed monoclonal antibody biosimilars, including the first domestically produced biosimilar, Hanlikang® (Rituximab), the first Sino-European dual-approved domestic monoclonal antibody biosimilar, Hanquyou® (Trastuzumab), Handayuan® (Adalimumab), and Hanbeitai® (Bevacizumab).

Adhering to the internal and external cultivation innovation and development strategy, Henlius has established a highly efficient innovation organization with two innovation centers in Shanghai, China, and California, USA. This has enabled the company to build a differentiated and diversified pipeline of innovative biopharmaceuticals covering multiple targets. With a differentiated development strategy of Combo+Global, Henlius is actively developing combination therapies based on Sulinmonab (anti-PD-1 monoclonal antibody), advancing multiple clinical trials globally.

By seizing the opportunity of tumor immunotherapy, Henlius aims to provide affordable and more effective treatment options. Henlius has established a fully integrated global R&D platform and has developed a diverse and high-quality pipeline with more than 20 candidate innovative monoclonal antibodies and tumor immunotherapy combinations. The company owns three production bases with a current commercial capacity of 48,000 liters, which is expected to reach 144,000 liters by 2026.

The production bases have obtained various certifications, including China GMP, EU GMP, and EU QP. Henlius has built a professional, efficient, and international commercial core team to cover market promotion, channel management, pricing, market access, domestic sales, and strategic planning. The team consists of over 800 professionals.

In addition to the Chinese market, Henlius has partnered with various overseas partners to fully cover the mainstream biopharmaceutical markets in Europe, the United States, and many emerging markets. Overall, Henlius | 复宏汉霖 is committed to driving the development and accessibility of innovative biologics, providing patients worldwide with high-quality treatment options in the fields of oncology and autoimmune diseases